Based on phase I and II trials, phase III clinical trials (NCT01604343, NCT01606761, NCT02019472, NCT01689532, NCT01856309) for inflammatory diseases (RA, SLE) have been completed, and SRK produces therapeutic effects and adverse reactions that are comparable to other IL-6 blockers, showing a longer half-life (>15 days) and decreased levels of CRP (a nonspecific marker of inflammation activation), and a few ADA occurred. Here, IL6 is linked to rheumatoid arthritis.